GERD Treatments Need Further Study, BlueCross BlueShield Assessment Finds
This article was originally published in The Gray Sheet
Executive Summary
Gastroesophageal reflux disease reimbursement trials should include control groups to discount placebo-effects, according to the BlueCross BlueShield Technology Evaluation Center
You may also be interested in...
Inaugural AHRQ Comparative Review Questions GERD Device Therapy Data
Clinical trial data on endoscopic treatments for gastroesophageal reflux disease, or GERD, is not up to par with the available research on pharmaceutical or surgical options, according to the Agency for Healthcare Research & Quality
Inaugural AHRQ Comparative Review Questions GERD Device Therapy Data
Clinical trial data on endoscopic treatments for gastroesophageal reflux disease, or GERD, is not up to par with the available research on pharmaceutical or surgical options, according to the Agency for Healthcare Research & Quality
Enteryx reimbursement
Results from Boston Scientific's ongoing U.S. and European gastrointestinal reflux disease treatment randomized placebo studies will be used to obtain private payor coverage. The 60-patient European study completed enrollment March 3, and enrollment for the 120-patient U.S. study is expected to conclude this summer. Both trials feature equal-sized treatment and placebo arms, with one-, three- and 12-month follow up. Enteryx recently received a CPT code for Medicare outpatient payment (1"The Gray Sheet" Nov. 24, 2003, In Brief)...